+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 125 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4896149
The immunoglobulin market is expected to record a CAGR of 6.5% over the forecast period, 2022-2027.

Globally, the outbreak of COVID-19 in 2020 was one of the greatest infectious challenges in recent times. Currently, few treatment options exist, and the availability of vaccines in some countries. There is an urgent need for effective therapies in the treatment of patients with COVID-19 infection. The use of immunoglobulin in the treatment of COVID-19 infection can be effective in managing the disease. For instance, according to a research study by Alan A. Nguyen et al. published in Clinical Immunology Journal 2020, the use of immunoglobulins in the treatment of COVID-19 is effective but not without potential adverse consequences.

The immunoglobulin market is expected to show rapid growth due to the rise in immunodeficiency disease prevalence, increased immunoglobulin adoption, and growing research and development activities.

The spatial patterns of the genome have been identified for treating several medical conditions, which has resulted in the implementation of spatial information as a diagnostic biomarker for various diseases. There is a growing demand for biomarkers that enables the differentiation of benign tumors from malignant tumors with higher accuracy, boosting the demand for spatial genomic analysis as a cancer diagnostic tool. Therefore the cumulative demand for robust cancer diagnostic solutions helps in the growth of the overall market.

Increasing research and development activities in developing new products to manage diseases is expected to drive market growth. For instance, in January 2019, Kedrion Biopharma received United States Food and Drug Administration approval for conducting a clinical trial to assess the efficacy and safety of a 10% intravenous immunoglobulin in the treatment of patients with primary immunodeficiency diseases (PID).

The market players are involved in the development of innovative drugs and discovering new therapeutic areas for the existing drugs. For instance, as per the National Clinical Trial (NCT) Registry, in February 2020, in China, Peking Union Medical College Hospital, in collaboration with Tongji Hospital of Tongji Medical College and Huazhong University of Science and Technology, initiated a phase II/Phase III clinical trial to assess the efficacy and safety of intravenous immunoglobulin (IVIG) for severe 2019 novel coronavirus (2019-nCoV) pneumonia. However, the stringent government regulations and the high cost of therapy are expected to impede the market growth over the forecast period.

Key Market Trends

By Application, the Hypogammaglobulinemia Segment is Expected to Hold Significant Market Share During the Forecast Period

Hypogammaglobulinemia is a condition in which enough gamma globulins are not produced in the blood. The major factor driving the hypogammaglobulinemia segment growth includes a significant increase in the prevalence of hypogammaglobulinemia disorders across the globe.

Globally, COVID-19 has become a great health challenge. Patients with cancer, especially hematologic malignancies, are at high risk for COVID-19 infection. For instance, according to a research article by Sukru Cekic et al., published in the Journal of Clinical Immunology 2021, protective measures against COVID-19 infection were high in primary immunodeficiencies (PIDs) patients with hypogammaglobulinemia receiving Ig replacement therapy. Moreover, female patients with primary immunodeficiencies and hypogammaglobulinemia increased concerns about COVID-19 infection.

Hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs) and invasive pneumococcal disease (IPD). According to a research study by Juthaporn Cowan et al., published in Clinical Infectious Diseases Journal 2017, as per study results, the high and low estimates of the prevalence of hypogammaglobulinemia were 31.6% and 13.5%, respectively. In Canada, hypogammaglobulinemia was present in at least 13.5% of invasive pneumococcal disease (IPD) cases. Secondary hypogammaglobulinemia is especially common in hematological malignancies and invasive pneumococcal disease (IPD) cases.

According to a research study by Namrata Singh et al., published in the British Society for Haematology Journal 2020, a high prevalence of hypogammaglobulinemia was found in newly diagnosed chronic lymphocytic lymphoma (CLL) patients. Patients with a low IgA or IgE were associated with higher-stage chronic lymphocytic lymphoma (CLL).

Furthermore, hypogammaglobulinemia can be observed at extremes of age, which were reported in the elderly population. In adults, hypogammaglobulinemia may be seen in hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Thus, the increasing prevalence of the elderly population and hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are expected to drive the segment growth over the forecast period.

North America is Expected to Dominate the Immunoglobulin Market Over the Forecast Period

The major factors driving the market growth in North America include rising healthcare expenditure, a growing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and increasing inclination of clinicians toward immunodeficiency therapies.

In the United States, the impact of COVID-19 on the immunoglobulin market is positive as there have been increasing research studies on immunoglobulins as an effective therapy in the treatment of COVID-19. For instance, according to the National Clinical Trial (NCT) Registry, as of 9th March 2021, in the United States, there was around 50 immunoglobulin-based ongoing clinical trials across different phases of development which shows a positive impact on the market as this can lead to the development of new effective therapy for COVID-19 in the near future.

The market players in the United States adopted various strategies such as product launches, developments, collaborations, mergers, and acquisitions in order to increase market share. For instance, in July 2019, ADMA Biologics Inc. received approval from the United States Food and Drug Administration (FDA) for license transfer of BIVIGAM from Biotest Pharmaceuticals Corporation, which began the commercial sales of the product.

Furthermore, in April 2019, ADMA Biologics Inc. received approval from the United States Food and Drug Administration (FDA) for ASCENIV, a novel intravenous immunoglobulin in the treatment of primary humoral immunodeficiency disease. Thus, the above-mentioned factors are expected to drive market growth over the forecast period.

Competitive Landscape

The immunoglobulin market is moderately competitive. The key manufacturers are found to offer technologically advanced techniques and platforms for a better understanding of disease biology and the introduction of novel therapeutics. Some of the global immunoglobulin market players are Baxter International Inc., CSL Ltd, Octapharma AG, Kedrion Biopharma Inc., Grifols SA, and Biotest AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Immunodeficiency Diseases
4.2.2 Increase in Adoption of Immunoglobulin
4.2.3 Growing Research and Development Activities
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.3.2 High Cost of Therapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 IgG
5.1.2 IgA
5.1.3 IgM
5.1.4 IgE
5.1.5 IgD
5.2 By Mode of Delivery
5.2.1 Intravenous Mode of Delivery
5.2.2 Subcutaneous Mode of Delivery
5.3 By Application
5.3.1 Hypogammaglobulinemia
5.3.2 Chronic Inflammatory demyelinating polyneuropathy (CIDP)
5.3.3 Immunodeficiency Disease
5.3.4 Myasthenia Gravis
5.3.5 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Baxter international Inc.
6.1.2 CSL Ltd
6.1.3 Grifols SA
6.1.4 Octapharma AG
6.1.5 Kedrion Biopharma Inc.
6.1.6 LFB group
6.1.7 Biotest AG
6.1.8 China Biologics Products Inc.
6.1.9 Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd
6.1.10 Bayer Healthcare
6.1.11 Takeda Pharmaceutical Company Limited
6.1.12 Bio Products Laboratory
6.1.13 Sanquin Plasma Products BV
6.1.14 Evolve Biologics Inc.
6.1.15 Pfizer Inc.
6.1.16 Shanghai RAAS Blood Products Co. Ltd
6.1.17 ADMA Biologics Inc.
6.1.18 Johnson & Johnson (Omrix Biopharmaceuticals Inc.)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Baxter international Inc.
  • CSL Ltd
  • Grifols SA
  • Octapharma AG
  • Kedrion Biopharma Inc.
  • LFB group
  • Biotest AG
  • China Biologics Products Inc.
  • Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd
  • Bayer Healthcare
  • Takeda Pharmaceutical Company Limited
  • Bio Products Laboratory
  • Sanquin Plasma Products BV
  • Evolve Biologics Inc.
  • Pfizer Inc.
  • Shanghai RAAS Blood Products Co. Ltd
  • ADMA Biologics Inc.
  • Johnson & Johnson (Omrix Biopharmaceuticals Inc.)